

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October 12, 1999

Betty J. Zea
Name of Person Depositing Correspondence

Betty J. Zea
Signature of Person Depositing Correspondence



RECEIVED
OCT 20 1999

TECH CENTER 1600/2900

Case 7247M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :
DOUGLAS JOSEPH DOBROZSI :
Serial No. 09/361,542 : Group Art Unit 1615
Filed July 27, 1999 : Examiner
For ORAL LIQUID :
MUCOADHESIVE :
COMPOSITIONS :

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, record is being made below of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 CFR §1.98(h) this Information Disclosure Statement does not constitute an admission of any kind and specifically is not an admission that the documents listed on attached form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 CFR §1.56(b).

Presented below are comments based on English abstracts of the non-English documents listed in PTO-1449 form. These comments are believed to be a fair representation of the contents of the non-English documents:

- JP 51142524, Reference 7, relates to finely granular anti-ulcer agents of improved stomach retention time which are coated with silicic acid.
- FR 2346017, Reference 8, relates to compositions for treatment of gastro-intestinal disorders containing beidellitic intergrade smectite.

Presented below are comments based upon an English translation for the non-English documents listed in the PTO-1449 form. The translation is believed to be accurate, but is not warranted as such. These comments are believed to be a fair representation of the contents of the non-English documents:

- RO 80,056, Reference 9, relates to a process for creating sodium and magnesium aluminosilicates in the form of tablets with complex anti-ulcer action for protection of the intestinal and gastric mucosa.
- RO 76,076, Reference 10, relates to a gel containing Na-alginate, aluminum phosphate, Weegum, etc. with a protective effect on the gastric mucosa and an antidote against radionuclides.
- EP 062,578, Reference 11, relates to compositions comprising at least two mineral substances: titanium oxide at a level of 5% or greater, as a coating agent and thixotrope, and an antacid.
- WO 97/12600, Reference 29, relates to a composition for vaginal dryness with 17B-estradiol and salts, a bioadhesive gelling hydrophilic agent, a gelling agent of the lipophilic agent (which can be colloidal silica), and a water-dispersible agent.
- Eros, I., et al., Reference 14, investigated the dependence between the concentration of inorganic colloid and the rheological nature of the system and the dependence between the physical and chemical characteristics of the liquid phase and the rheological characteristics of Aerosil.
- Droy-Lefaix, M.T., Reference 19, relates to a discussion of the structure of smectit, as well as absorption, spreading and protective (from certain bacteria and virus) characteristics on the intestinal mucosa. This reference also discusses its interaction with glycoproteins.

Copies of the cited documents are attached. It is respectfully requested that the documents be carefully considered by the Examiner and made of record in the case.

Respectfully submitted,
DOUGLAS JOSEPH DOBROZSI

By Betty J. Zea
Betty J. Zea
Attorney for Applicant(s)
Registration No. 36,069
(513) 622-3952

October 12, 1999
The Procter & Gamble Company
Health Care Research Center (Box 1050)
8700 Mason Montgomery Rd.
Mason, OH 45040